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Insuring Rapid and Robust Safety Assessment
To the Editor:
Our research has emphasized the dose-related risk of
squamous cell cancer with PUVA (psoralen and ultraviolet-
A) (Stern et al, 1984). Therefore, low-dose exposure is likely
to have low persistent risk. When we limited our analysis to
patients with substantial exposure to PUVA, however, our
estimates of persistence did not change substantially (data
not shown), suggesting that Paul’s criticism concerning
generalizability to patients treated with comparable doses is
unfounded (Njisten et al, 2003).
Perhaps more importantly, Paul raises the issue of
conflict of interest. We agree with Paul that a true
collaboration among academic and non-academic investi-
gators, researchers from the pharmaceutical industry,
regulatory agents, and patients based on mutual respect
and continuous dialog in the evaluation of long-term safety
of psoriasis therapies is ideal (Paul, 2003). But as Paul
indicates, these parties may have different and sometimes
conflicting interests and incentives, which may affect their
perspectives, motivations, and goals.
Close relationships between academic institutes and
private companies are essential for biomedical progress.
Managing the tensions from conflicting expectations and
goals is complex. The optimal means to do so is not clear.
The fundamental goal of the academic enterprise is to
create knowledge. New medical knowledge is usually
transmitted through publication, which is also the major
currency of academic achievement. In clinical medicine, our
goal is to improve the public’s health. Insuring the safety of
medications is important in achieving this goal. Timely and
complete follow-up enhances the validity and impact of a
safety study as well as the probability that it will be published.
The primary goal of corporations is profit. Being the
bearer of bad news, (i.e., information that reduces profit/
sales) is unlikely to be career-building for a corporate
employee. Diffusion of responsibility (and credit) for a study
among employees and many distinguished individuals,
whose primary interests are elsewhere, is unlikely to provide
the high-level motivation and focus needed for optimal
execution of a complex long-term study. Commercial
sponsorship is associated with more positive assessments
of drugs (Als-Nielsen et al, 2003).
A comparison of completeness of follow-up at compar-
able times in the PUVA Follow-Up Study and Dr Paul’s study
is instructional. PUVA therapy for psoriasis was described in
1974, multiple clinical trials were organized in 1975, and first
results published in 1977 (Melski et al, 1977). As Dr Paul
noted, we published our first observations concerning long-
term safety in 1979 (Stern et al, 1979). In 1984, we published
a more definitive work, which demonstrated the increased
rise of squmous cell carcinoma, (SCC) with PUVA (Stern
et al, 1984). We based this analysis on standardized
dermatologic exam for 94% of patients at least 4 years
after first treatment and had follow-up interview on more
than 95% of survivors at this time (Stern et al, 1984).
The use of cyclosporin for psoriasis was first described
in 1979 (Mueller and Herman,1979). In 1986, the results of
controlled clinical trials were published (Ellis et al, 1986). In
spite of safety concerns about cyclosporin and its high cost,
nearly 25 years elapsed from the first use of this therapy for
psoriasis and Paul’s publication, which was based on
follow-up data for five years but included only half of
originally enrolled patients at that time (Paul et al, 2003).
Since the health of patients and rational decision-making
are best supported by robust and rapidly completed safety
studies, we believe that these differences support the PUVA
model (investigator initiated and funded without direct
corporate control) as the preferable model for long-term
safety studies of treatments of chronic diseases.
Recently, the Food and Drug Administration (FDA)
expressed great concern about the compliance and time-
liness of pharmaceutical companies in completing post-
marketing studies. Between 1991 and 2000, 1090 new drug
applications were approved by the FDA, which generated
a total of 2328 postmarketing commitments. Of these, only
37% were completed (Center for Drug Evaluation and
Research, 2003a). This observation prompted ‘‘the Moder-
nization Act’’, which added a new provision on postmarket-
ing studies to the Federal Food, Drug, and Cosmetic Act.
This new provision requires sponsors of approved drugs
and biological products to report to the FDA annually on the
progress of their postmarketing study commitments (Center
for Drug Evaluation and Research, 2003b). Unfortunately, a
requirement to publish negative findings is lacking and the
track record of some pharmaceutical companies in sup-
pressing ‘‘negative’’ news is not reassuring (Rennie, 1997).
When science suggests a potential substantial long-term
treatment risk, long-term safety studies are essential.
(Stern, 2003) We believe that the facts support our opinion
that these complex studies are most likely to succeed if
trained and independent investigators design, control, and
analyze them. We must look to industry to fund these
investigators, but industry should give them independence.
We believe that this model best serves our patients and the
enlightened self-interest of companies.
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